We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment.
- Authors
Martinez-Naharro, Ana; Patel, Rishi; Kotecha, Tushar; Karia, Nina; Ioannou, Adam; Petrie, Aviva; Chacko, Liza A; Razvi, Yousuf; Ravichandran, Sriram; Brown, James; Law, Steven; Quarta, Cristina; Mahmood, Shameem; Wisniowski, Brendan; Pica, Silvia; Sachchithanantham, Sajitha; Lachmann, Helen J; Moon, James C; Knight, Daniel S; Whelan, Carol
- Abstract
Aims To assess the ability of cardiovascular magnetic resonance (CMR) to (i) measure changes in response to chemotherapy; (ii) assess the correlation between haematological response and changes in extracellular volume (ECV); and (iii) assess the association between changes in ECV and prognosis over and above existing predictors. Methods and results In total, 176 patients with cardiac AL amyloidosis were assessed using serial N-terminal pro-B-type natriuretic peptide (NT-proBNP), echocardiography, free light chains and CMR with T1 and ECV mapping at diagnosis and subsequently 6, 12, and 24 months after starting chemotherapy. Haematological response was graded as complete response (CR), very good partial response (VGPR), partial response (PR), or no response (NR). CMR response was graded by changes in ECV as progression (≥0.05 increase), stable (<0.05 change), or regression (≥0.05 decrease). At 6 months, CMR regression was observed in 3% (all CR/VGPR) and CMR progression in 32% (61% in PR/NR; 39% CR/VGPR). After 1 year, 22% had regression (all CR/VGPR), and 22% had progression (63% in PR/NR; 37% CR/VGPR). At 2 years, 38% had regression (all CR/VGPR), and 14% had progression (80% in PR/NR; 20% CR/VGPR). Thirty-six (25%) patients died during follow-up (40 ± 15 months); CMR response at 6 months predicted death (progression hazard ratio 3.82; 95% confidence interval 1.95–7.49; P < 0.001) and remained prognostic after adjusting for haematological response, NT-proBNP and longitudinal strain (P < 0.01). Conclusions Cardiac amyloid deposits frequently regress following chemotherapy, but only in patients who achieve CR or VGPR. Changes in ECV predict outcome after adjusting for known predictors.
- Subjects
BRAIN natriuretic factor; MAGNETIC resonance; IMMUNOGLOBULIN light chains; AMYLOIDOSIS; CARDIAC amyloidosis
- Publication
European Heart Journal, 2022, Vol 43, Issue 45, p4722
- ISSN
0195-668X
- Publication type
Article
- DOI
10.1093/eurheartj/ehac363